TimesSquare Capital Management LLC increased its stake in Cencora, Inc. (NYSE:COR - Free Report) by 2.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 544,248 shares of the company's stock after buying an additional 15,464 shares during the quarter. Cencora makes up 1.8% of TimesSquare Capital Management LLC's holdings, making the stock its 4th biggest position. TimesSquare Capital Management LLC owned about 0.28% of Cencora worth $122,282,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors also recently made changes to their positions in COR. Swedbank AB raised its holdings in Cencora by 2.3% in the 3rd quarter. Swedbank AB now owns 1,394,449 shares of the company's stock valued at $313,863,000 after acquiring an additional 31,104 shares during the period. Blue Trust Inc. raised its holdings in Cencora by 108.7% in the 3rd quarter. Blue Trust Inc. now owns 2,776 shares of the company's stock valued at $625,000 after acquiring an additional 1,446 shares during the period. Capital Investment Advisors LLC raised its holdings in Cencora by 35.4% in the 3rd quarter. Capital Investment Advisors LLC now owns 1,334 shares of the company's stock valued at $300,000 after acquiring an additional 349 shares during the period. Northwest Investment Counselors LLC bought a new position in Cencora in the 3rd quarter valued at about $70,000. Finally, Whittier Trust Co. raised its holdings in Cencora by 1.0% in the 3rd quarter. Whittier Trust Co. now owns 7,812 shares of the company's stock valued at $1,758,000 after acquiring an additional 81 shares during the period. Institutional investors and hedge funds own 97.52% of the company's stock.
Insider Buying and Selling
In other Cencora news, Chairman Steven H. Collis sold 50,000 shares of the firm's stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $243.97, for a total value of $12,198,500.00. Following the sale, the chairman now owns 326,557 shares in the company, valued at $79,670,111.29. This trade represents a 13.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Silvana Battaglia sold 1,678 shares of the firm's stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the sale, the executive vice president now owns 20,329 shares in the company, valued at $4,649,648.88. This represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. 10.80% of the stock is currently owned by company insiders.
Cencora Price Performance
Shares of NYSE COR traded down $3.16 during trading hours on Thursday, hitting $242.26. 350,014 shares of the stock were exchanged, compared to its average volume of 1,475,073. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The company has a market cap of $46.98 billion, a PE ratio of 34.46, a price-to-earnings-growth ratio of 1.29 and a beta of 0.49. The company's fifty day simple moving average is $239.11 and its two-hundred day simple moving average is $237.42. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $262.26.
Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, sell-side analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.
Cencora Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Investors of record on Friday, February 14th will be given a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.91%. Cencora's dividend payout ratio is 31.29%.
Wall Street Analysts Forecast Growth
Several research analysts have weighed in on COR shares. Robert W. Baird increased their price target on shares of Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a report on Thursday, November 7th. UBS Group increased their price target on shares of Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a report on Thursday, November 7th. Wells Fargo & Company increased their price target on shares of Cencora from $237.00 to $251.00 and gave the company an "equal weight" rating in a report on Wednesday, January 29th. Mizuho began coverage on shares of Cencora in a report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 target price on the stock. Finally, Evercore ISI raised their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a report on Thursday, February 6th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $277.90.
Read Our Latest Analysis on COR
Cencora Profile
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Recommended Stories
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
